New CEO incoming as resilient Roche maintains modest growth

21 July 2022

Swiss drugmaker Roche (ROG: SIX) announced its financial results for the first half of 2022 on Thursday, as well as revealing that chief executive Severin Schwan will step down next March after 15 years in the top job.

Dr Schwan will become chairman of the board of directors at that point, taking over from Christoph Franz, while Thomas Schinecker (pictured) will be the new CEO.

"Thanks to the ongoing renewal of our portfolio, we continue to grow despite biosimilars"Dr Schinecker is the current head of Roche’s Diagnostics division, having been with the company in different leadership positions since 2003.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK